Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

SIMPLE SUMMARY: Patients with platinum-resistant ovarian cancer experience poor prognosis. No mature evidence supports the routine adoption of immunotherapy alone in this setting. However, the combination of immunotherapy with target therapies seems to be a promising option in patients with ovarian...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Autores principales: Indini, Alice, Nigro, Olga, Lengyel, Csongor György, Ghidini, Michele, Petrillo, Angelica, Lopez, Salvatore, Raspagliesi, Francesco, Trapani, Dario, Khakoo, Shelize, Bogani, Giorgio
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8037571/
https://ncbi.nlm.nih.gov/pubmed/33916221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13071663
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares